Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Publisher Correction: Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption.

Ray VA, Hill PJ, Stover CK, Roy S, Sen CK, Yu L, Wozniak DJ, DiGiandomenico A.

Sci Rep. 2018 Jun 20;8(1):9637. doi: 10.1038/s41598-018-26660-6.

2.

Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption.

Ray VA, Hill PJ, Stover CK, Roy S, Sen CK, Yu L, Wozniak DJ, DiGiandomenico A.

Sci Rep. 2017 Nov 22;7(1):16065. doi: 10.1038/s41598-017-16215-6. Erratum in: Sci Rep. 2018 Jun 20;8(1):9637.

3.

CysK Plays a Role in Biofilm Formation and Colonization by Vibrio fischeri.

Singh P, Brooks JF 2nd, Ray VA, Mandel MJ, Visick KL.

Appl Environ Microbiol. 2015 Aug;81(15):5223-34. doi: 10.1128/AEM.00157-15. Epub 2015 May 29.

4.

Identification of a novel matrix protein that promotes biofilm maturation in Vibrio fischeri.

Ray VA, Driks A, Visick KL.

J Bacteriol. 2015 Feb;197(3):518-28. doi: 10.1128/JB.02292-14. Epub 2014 Nov 17.

5.

The putative oligosaccharide translocase SypK connects biofilm formation with quorum signaling in Vibrio fischeri.

Miyashiro T, Oehlert D, Ray VA, Visick KL, Ruby EG.

Microbiologyopen. 2014 Dec;3(6):836-48. doi: 10.1002/mbo3.199. Epub 2014 Sep 25.

6.
7.

LuxU connects quorum sensing to biofilm formation in Vibrio fischeri.

Ray VA, Visick KL.

Mol Microbiol. 2012 Nov;86(4):954-70. doi: 10.1111/mmi.12035. Epub 2012 Oct 5.

8.

A semi-quantitative approach to assess biofilm formation using wrinkled colony development.

Ray VA, Morris AR, Visick KL.

J Vis Exp. 2012 Jun 7;(64):e4035. doi: 10.3791/4035.

9.

Identification and characterization of noncoding small RNAs in Streptococcus pneumoniae serotype 2 strain D39.

Tsui HC, Mukherjee D, Ray VA, Sham LT, Feig AL, Winkler ME.

J Bacteriol. 2010 Jan;192(1):264-79. doi: 10.1128/JB.01204-09.

10.

Preclinical toxicology studies with azithromycin: genetic toxicology evaluation.

Amacher DE, Ellis JH Jr, Joyce AJ, Muehlbauer PA, Turner GN, Wahrenburg MG, Holden HE, Ray VA.

Mutat Res. 1993 Jul;300(2):79-90.

PMID:
7685497
12.

Relevancy issues.

Ray VA.

Ann N Y Acad Sci. 1983;407:362-6. No abstract available.

PMID:
6576680
13.

Roundtable discussion. Research priorities and perspectives: industry, universities, government.

Hollaender A, Ray VA, Mendelsohn ML, Lyons J, Valentine RC, Colton R, Rominger R.

Basic Life Sci. 1982;21:509-32. No abstract available.

PMID:
7150205
14.

Approaches to the genetic safety evaluation of agricultural chemicals.

Ray VA.

Basic Life Sci. 1982;21:45-56. No abstract available.

PMID:
7150204
15.

An evaluation of the Escherichia coli WP2 and WP2 uvrA reverse mutation assay.

Brusick DJ, Simmon VF, Rosenkranz HS, Ray VA, Stafford RS.

Mutat Res. 1980 Sep;76(2):169-90.

PMID:
7005668
16.

Point mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells. II. Test validation and interpretation.

Amacher DE, Paillet SC, Turner GN, Ray VA, Salsburg DS.

Mutat Res. 1980 Aug;72(3):447-74.

PMID:
7453708
17.
18.

Application of microbial and mammalian cells to the assessment of mutagenicity.

Ray VA.

Pharmacol Rev. 1978 Dec;30(4):537-46. Review. No abstract available.

PMID:
392545
19.

A comparative study on the genetic effects of hycanthone and oxamniquine.

Ray VA, Holden HE, Ellis JH Jr, Hyneck ML.

J Toxicol Environ Health. 1975 Nov;1(2):211-7.

PMID:
1107579
20.

DD-carboxypeptidase and peptidoglycan transpeptidase from Pseudomonas aeruginosa.

Presslitz JE, Ray VA.

Antimicrob Agents Chemother. 1975 May;7(5):578-81.

21.

Some primary considerations in the interpretation of the dominant-lethal assay.

Ray VA, Hyneck ML.

Environ Health Perspect. 1973 Dec;6:27-35. No abstract available.

22.

Mutagenicity studies with 6-mercaptopurine. I. Cytogenetic activity in vivo.

Holden HE, Ray VA, Wahrenburg MG, Zelenski JD.

Mutat Res. 1973 Nov;20(2):257-63. No abstract available.

PMID:
4753929
23.
24.

A study of triflupromazine in dominant-lethal, cytogenetic and host-mediated assays.

Ray VA, Holden HE, Ellis JH, Hyneck ML.

Mutat Res. 1973 Jun;18(3):301-9. No abstract available.

PMID:
4712310
25.

Carbenicillin indanyl sodium, an orally active derivative of carbenicillin.

English AR, Retsema JA, Ray VA, Lynch JE.

Antimicrob Agents Chemother. 1972 Mar;1(3):185-91.

26.

Carbenicillin: chemistry and mode of action.

Butler K, English AR, Ray VA, Timreck AE.

J Infect Dis. 1970 Sep;122:Suppl:S1-8. No abstract available.

PMID:
4248289

Supplemental Content

Support Center